CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 54 enrolled
Drug / intervention
Aflibercept (Eylea, BAY 86-5321) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02396316
NCT02396316Phase 3Completed
CompareCT.gov

A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

Bayer·interventional·Posted Mar 24, 2015·Updated Sep 15, 2017

In Brief

A Phase 3 clinical trial evaluating Aflibercept (Eylea, BAY 86-5321) and Sham Injection for Glaucoma, Neovascular. Completed, enrolled 54 participants across 19 sites.

Detailed Summary

To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Neovascular
CountriesJapan
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 24, 2015
Enrollment StartApr 2, 2015
Primary CompletionJun 16, 2016
Study CompletionSep 6, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.3 years ago

Interventions

Aflibercept (Eylea, BAY 86-5321)drug

After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.

Sham Injectiondrug

After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.